Viva Biotech's 2025 Annual Report Highlights AI Advancements in Drug Discovery and CDMO Growth

Overview of 2025 Financial Performance

On March 30, 2026, Viva Biotech Holdings delivered its annual results for 2025, revealing a substantial revenue growth that reached RMB 1,729.4 million. The gross profit was reported at RMB 655.6 million, with a gross profit margin of 37.9%, showing a notable year-over-year increase of 3.3 percentage points. The net profit also surged to RMB 269.3 million, marking an impressive increase of 21.3% compared to the previous year. Furthermore, adjusted non-IFRS net profit saw an increase to RMB 335.3 million, up nearly 6.6%.

Growth in CRO Business

Viva Biotech's Contract Research Organization (CRO) arm demonstrated resilience and reporting revenue rose to RMB 848.6 million, up 4.7% from last year's figures. The number of CRO clients notably increased to 1,866, including the world's top ten pharmaceutical companies, which contributed approximately 25.7% of the total revenue. The company's continuous innovation has allowed it to deliver over 98,885 protein structures to clients, with 16,169 new structures delivered within 2025 alone.

The company’s AI-driven drug discovery (AIDD) technology now supports 196 ongoing projects, with a growing client base purchasing these cutting-edge services. Revenue derived from AI-enabled initiatives accounted for about 12.0% of total CRO revenue, emphasizing the strategic importance of AI in enhancing drug discovery processes.

Innovations in CDMO Projects

In its initiative to provide a comprehensive service platform, Viva Biotech successfully launched two new commercial projects under its Contract Development and Manufacturing Organization (CDMO). These projects are forecasted to yield substantial growth opportunities, particularly as they near commercial production status. During the reporting period, the CMC (Chemistry, Manufacturing, and Controls) business recorded a higher project delivery rate, reflecting the optimization of its client structure. Interestingly, internal referrals within Viva contributed to 55.0% of customer order volume, highlighting the strength of its integrated strategy.

Gains from Incubation Portfolio

In addition to its main lines of business, Viva Biotech made considerable strides with its incubation portfolio, achieving nearly RMB 83.6 million in returns through successful exits from multiple companies. As of December 31, 2025, the firm had invested in 93 start-ups, with 19 incubated projects reaching full or partial exits. This strategy is instrumental in fostering innovation across the biotech landscape.

Workforce and Facility Expansion

By year-end 2025, Viva Biotech employed 2,169 individuals, including 1,123 in CRO R&D, reflecting a strategic push to expand its technical capabilities. The company has also been developing its laboratory and office facilities to align with its ambitious growth plans, ensuring its operational capabilities keep pace with the fast-evolving biotech environment.

In summary, Viva Biotech's 2025 annual report underscores its remarkable achievements in revenues, innovations in AI-driven drug discovery, and strengthening CDMO offerings. This positions the company at the forefront of the biotech industry as it prepares for future advancements.